Depomed's Expanded Portfolio Of Pain Management Products Led By The NUCYNTA® Franchise To Be Highlighted At PAINWeek® 2015
- Spotlighting Early Success of Re-Launch and New Product Positioning of Potential Blockbuster NUCYNTA® -
- NUCYNTA ER and Gralise® Product Theatre Symposia to Explore Meeting the Unmet Medical Needs of Patients with Pain -
NEWARK, Calif., Sept. 2, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced today its participation at PAINWeek® 2015, the nation's largest annual meeting for frontline clinicians in the area of pain management, to be held September 8-12, 2015 in Las Vegas.
"Depomed's significant presence at PAINWeek 2015 will highlight our recent achievements towards building one of the most complete and highly differentiated pain portfolios in the industry," said Scott Shively, Senior Vice President and Chief Commercial Officer of Depomed.
Depomed is pleased to be sponsoring the following two product symposia:
Product Theatre
NUCYNTA ER Symposium Title: "Targeting Success: An Interactive Discussion of a Next Generation Molecule"
| Scope: |
This interactive session will explore tapentadol, designed as a next generation opioid molecule, its potential mechanism of action, appropriate dosing and titration as well as patient selection. |
| Facilitators: |
Gregory Holmquist, PharmD, CPE, A clinical pain management and palliative care pharmacist, consultant with Seattle's Group Health and owner of Palliative Care Strategies |
| Steve E. Vacalis, DO, Family Medicine Physician, CaroMont Regional Medical Center |
|
| Joseph V. Pergolizzi, Jr., MD, Adjunct Assistant Professor Department of Medicine at Johns Hopkins University School of Medicine, Adjunct Faculty Member Department of Anesthesiology and Pain Medicine at Georgetown University School of Medicine and Associate Professor Department of Pharmacology at Temple University School of Medicine |
|
| Date/Time: |
Wednesday, September 9, from 12:15 p.m. – 1:30 p.m. |
| Location: |
The Chelsea Theatre, Level 3, Cosmopolitan Hotel |
Gralise Symposium Title: "The Treatment of PHN: Unmet Needs Still Exist"
| Scope: |
This interactive session will discuss what therapeutic options exist to address unmet needs in the treatment of Post-Herpetic Neuralgia (PHN) over a 24-hour period (Night & Day). |
| Facilitator: |
Gregory Holmquist, PharmD, CPE, A clinical pain management and palliative care pharmacist, consultant with Seattle's Group Health Cooperative and owner of Palliative Care Strategies |
| Date/Time: |
Wednesday, September 9, from 8:00 a.m. – 8:55 a.m. |
| Location: |
Brera Ballroom, Level 3, Cosmopolitan Hotel |
In addition, Depomed is pleased to be sponsoring the following education symposium:
Continuing Medical Education (CME) Symposium
| Title: |
"Multimodal Approaches to the Treatment of Mixed Pain: What is New?" |
| Scope: |
The activity will address the learning gap among clinicians treating patients with pain, regarding appropriate approaches in the diagnosis of mixed pain conditions and to treatment strategies that address multiple pain pathways underlying these conditions. |
| Facilitator: |
Oscar de Leon-Casasola, MD, Vice-chair for Clinical Affairs and Professor of Anesthesiology (Tenure Track) Department of Anesthesiology and a Professor of Medicine University at Buffalo School of Medicine and Biomedical Sciences |
| Date/Time: |
Wednesday, September 9, from 7:00a.m. - 7:55a.m. |
| Location: |
Gracia 5, Level 3, Cosmopolitan Hotel |
Exhibit Booth
Depomed company representatives will be hosting conference attendees at its booth, #217.
About Depomed
Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Our NUCYNTA® franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and NUCYNTA® (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise, NUCYNTA ER and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com.
NUCYNTA®, Gralise® CAMBIA®, Zipsor®, Lazanda® and Acuform® are registered trademarks of Depomed, Inc.
PAINWeek® is a registered trademark of Aventine HealthSciences.
Investor Contact:
Depomed, Inc.
Christopher Keenan
510-744-8000
[email protected]
Media Contact:
Mark Corbae
Canale Communications for Depomed
619-849-5375
[email protected]
SOURCE Depomed, Inc.
Share this article